Reinhart Partners LLC. Buys 7,327 Shares of ICU Medical, Inc. $ICUI

Reinhart Partners LLC. raised its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 2.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 322,095 shares of the medical instruments supplier’s stock after buying an additional 7,327 shares during the quarter. Reinhart Partners LLC.’s holdings in ICU Medical were worth $51,699,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of ICU Medical in the second quarter worth $550,250,000. Jupiter Topco LLC bought a new stake in ICU Medical during the second quarter worth about $407,786,000. Janus Henderson Group PLC grew its stake in ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after buying an additional 99,256 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in ICU Medical by 6.8% during the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after buying an additional 63,026 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in ICU Medical in the 2nd quarter valued at about $54,059,000. 96.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ICUI shares. Raymond James Financial restated a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. BTIG Research boosted their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Zacks Research cut ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

Insider Transactions at ICU Medical

In other news, VP Virginia Sanzone sold 4,856 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total value of $819,158.64. Following the completion of the transaction, the vice president directly owned 14,604 shares in the company, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Christian Voigtlander sold 8,929 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares of the company’s stock, valued at approximately $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 21,830 shares of company stock valued at $3,905,003. Corporate insiders own 2.10% of the company’s stock.

ICU Medical Stock Up 2.0%

ICUI stock opened at $160.32 on Friday. The stock has a market capitalization of $4.01 billion, a P/E ratio of 135.86, a price-to-earnings-growth ratio of 1.98 and a beta of 0.86. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85. The firm has a 50-day moving average price of $168.41 and a 200-day moving average price of $148.25.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, equities research analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and critical care. Its products support the delivery of medications, fluids, and nutrition while helping healthcare providers reduce the risk of complications associated with intravenous treatment.

The company’s product portfolio includes infusion pumps and related administration sets, needle-free connectors, vascular access devices, intravenous systems, and other products used in hospitals and alternate-care settings.